Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.

Medicine - 1 Nov 2015

Liu Weisi, Fu Qiang, An Huimin, Chang Yuan, Zhang Weijuan, Zhu Yu, Xu Le, Xu Jiejie

Abstract excerpt

DNA sequencing revealed that mutations in SETD2 occur in 3% to 12% of clear-cell renal cell carcinoma (ccRCC) cases and are associated with poor clinical outcome. In this study, we used an immunohistochemistry (IHC) assay to evaluate the impact of SETD2 loss, with expression of H3K36me3, a nonredundantly histone modification by SETD2, on recurrence and survival of nonmetastatic ccRCC patients after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Histone-Lysine N-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Kidney Neoplasms

Share to Methyltransferases

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 26559293
DOI: 10.1097/MD.0000000000002004
PMCID: PMC4912287

Genes

SETD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.PMID 26559293Read ↗

Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.Semantic proximity Read ↗

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.Semantic proximity Read ↗

SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF ‐β‐independent mannerSemantic proximity Read ↗

Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.Semantic proximity Read ↗

SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formationSemantic proximity Read ↗

Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma.Semantic proximity Read ↗

Revealing the characteristics of SETD2-mutated clear cell renal cell carcinoma through tumor heterogeneity analysisSemantic proximity Read ↗

Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

SETD2: an epigenetic modifier with tumor suppressor functionality.Semantic proximity Read ↗

Deficiency of histone H3K36 methyltransferase SETD2 inhibits proliferation and migration of hepatocellular carcinoma through ERK pathwaySemantic proximity Read ↗

[Research progress on the expression and carcinogenic mechanisms of SETD2 in malignant tumors].Semantic proximity Read ↗

NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.